{"commentary":{"count":137,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":96,"youtube":22,"podcast":17,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04685135\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"KRYSTAL-12","nct_id":"NCT04685135","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krystal-12-nct04685135. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"KRYSTAL-12","arms":[{"description":null,"label":"MRTX849","type":"EXPERIMENTAL"},{"description":null,"label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-30","type":"ESTIMATED"},"conditions":["Metastatic Non Small Cell Lung Cancer","Advanced Non Small Cell Lung Cancer"],"enrollment":{"count":453,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"MRTX849","type":"DRUG"},{"name":"Docetaxel","type":"DRUG"}],"last_update":"2026-08-11","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-12-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Per Blinded Independent Central Review","timeFrame":"From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)"}],"references":[{"citation":"Barlesi F, Yao W, Duruisseaux M, Doucet L, Azkarate Martinez A, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, MichenzIe MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations. Future Oncol. 2026 Sep 16:1-12. doi: 10.1080/14796694.2026.2719409. Online ahead of print.","pmid":"42745627","type":"DERIVED"},{"citation":"Barlesi F, Yao W, Duruisseaux M, Doucet L, Martinez AA, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, Michenzie MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet. 2025 Aug 9;406(10503):615-626. doi: 10.1016/S0140-6736(25)00866-9.","pmid":"40783289","type":"DERIVED"}],"start_date":{"date":"2021-02-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","url":"https://clinicaltrials.gov/study/NCT04685135"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krystal-12-nct04685135"}